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Breast cancer is the commonest malignancy of women in
many parts of the world and comprises 18% of all female
cancers. There is one million new cases in the world each
year. Neopterin which is a pteridine produced by activa-
tion of monocytes by IFN-g may be used as a marker of
immune system activation. The biological function of
neopterin is still largely unknown and certain patho-
physiologic roles have only recently been elucidated.
Therefore, the aim of this work was to investigate the role
of neopterin in females with primary and metastatic breast
cancer. The obtained results were correlated with different
clinicopathological data of those patients. The study popu-
lation included females with primary and metastatic breast
cancer as well as healthy age matched females were taken
as a control group. Peripheral blood mononuclear cells
were separated from each subject under study by Ficoll-
Hypaque density gradient centrifugation technique. The
isolated cells were cultured with and without PHA and
neopterin levels were measured in serum and culture
supernatants by ELISA technique. The results showed that
neopterin levels were lowest in serum, followed by culture
supernatants without PHA and highest in culture superna-
tants with PHA in each studied group. The mean neop-
terin values in serum and culture supernatants with PHA
of metastatic breast cancer patients were significantly
higher than in the primary breast cancer patients and the
control group. Our results also indicated that neopterin
levels positively correlated with the tumor grade, tumor
stage and the presence of metastasis. From all mentioned
data it is clear that, measurement of neopterin either in
serum or in culture supernatants with or without PHA
can give an indication about immunological status of
breast cancer patients’ response to therapy and early
detection of metastasis. It gives an important and valuable
prognostic information before surgical intervention is
performed.
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